In re: EPIPEN (Epinephrine Injection, USP) Marketing, Sales Practices, and Antitrust Litigtion
Date Filed: August 3, 2017Status: Pending
District Court: District of Kansas – 17-MD-2785
Nature of Suit: Generic Competition Block or Delay|Antitrust
Defendant Type: Pharma
Plaintiff Type: Private
Case Info: http://ksd.uscourts.gov/index.php/mdlcase/epipen-epinephrine-injection-usp-marketing-sales-practices-and-antitrust-litigation/
Court Document: http://www.ksd.uscourts.gov/wp-content/uploads/2018/05/Amended-Complaint-Doc.-60.pdf; https://1.next.westlaw.com/Document/I3ed6b8f0786c11e7a3f3a229dca6c9c6/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad7401200000164d8d6778a73e32028%3FNav%3DCASE%26fragmentIdentifier%3DI3ed6b8f0786c11e7a3f3a229dca6c9c6%26startIndex%3D1%26contextData%3D%2528sc.Search%2529%26transitionType%3DSearchItem&listSource=Search&listPageSource=5315036cb47d1ebec27a7a5ab634e2f9&list=ALL&rank=1&sessionScopeId=85e11915b115540da19fba9d03581e331354750aa3dda2db8940d82bd3592589&originationContext=Search%20Result&transitionType=SearchItem&contextData=%28sc.Search%29
The plaintiffs in the case allege Mylan N.V. created and exploited an EpiPen monopoly by providing aggressive rebates and incentives to pharmacy benefit managers to exclude competitors, including Optum, from formularies. The court held that Centralized pretrial proceedings were warranted in five actions, pending in four districts.
Associated Legislation:
No items found
Leave A Comment